Last reviewed · How we verify
JNJ 28431754 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JNJ 28431754 (JNJ 28431754) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JNJ 28431754 TARGET | JNJ 28431754 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JNJ 28431754 CI watch — RSS
- JNJ 28431754 CI watch — Atom
- JNJ 28431754 CI watch — JSON
- JNJ 28431754 alone — RSS
Cite this brief
Drug Landscape (2026). JNJ 28431754 — Competitive Intelligence Brief. https://druglandscape.com/ci/jnj-28431754. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab